{
  "created_at": "Sat Jun 19 13:10:28 +0000 2021",
  "id_str": "1406231559254990853",
  "full_text": "AstraZeneca’s coronavirus antibody treatment failed in late-stage clinical trials to achieve its primary goal of preventing symptomatic Covid-19 in people recently exposed to the virus https://t.co/ZzqCrAAgM4",
  "display_text_range": [
    0,
    208
  ],
  "entities": {
    "hashtags": [],
    "symbols": [],
    "user_mentions": [],
    "urls": [
      {
        "url": "https://t.co/ZzqCrAAgM4",
        "expanded_url": "https://on.wsj.com/3cR0x3A",
        "display_url": "on.wsj.com/3cR0x3A",
        "indices": [
          185,
          208
        ]
      }
    ]
  },
  "user": {
    "name": "The Wall Street Journal",
    "screen_name": "WSJ",
    "profile_image_url_https": "https://pbs.twimg.com/profile_images/971415515754266624/zCX0q9d5_normal.jpg"
  },
  "retweet_count": 75,
  "favorite_count": 91,
  "possibly_sensitive": false,
  "original_created_at": "Sat Jun 19 12:45:04 +0000 2021",
  "localize": [
    {
      "locale": "ja",
      "full_text": "アストラゼネカ社のコロナウイルス抗体治療薬は、ウイルスにさらされたばかりの人の症候性コヴィド-19を予防するという主要な目標を達成することができず、後期臨床試験に失敗した https://t.co/ZzqCrAAgM4"
    },
    {
      "locale": "zh",
      "full_text": "阿斯利康公司的冠状病毒抗体治疗在后期临床试验中未能实现其主要目标，即防止最近接触病毒的人出现症状性的Covid-19https://t.co/ZzqCrAAgM4。"
    },
    {
      "locale": "zh-Hant",
      "full_text": "阿斯利康公司的冠狀病毒抗體治療在後期臨牀試驗中未能實現其主要目標，即防止最近接觸病毒的人出現症狀性的Covid-19https://t.co/ZzqCrAAgM4。"
    }
  ]
}